Divi's Laboratories vs Laurus Labs: Which Stock Should You Track

Divi's Laboratories vs Laurus Labs is a comparison pharma API investors look up when evaluating two of India's leading active pharmaceutical ingredient makers. Divi's Laboratories is one of the world's largest custom API manufacturers with a dominant share in select molecules for global innovators, while Laurus Labs is a high-growth API company with specialisation in ARV (antiretroviral) APIs, oncology APIs and a growing formulations business. Both are key suppliers to global generic and innovator pharma companies.

This Divi's Laboratories vs Laurus Labs article covers reach and market position, key products, latest declared results and stock valuation. The Divi's Laboratories vs Laurus Labs data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Divi's Laboratories vs Laurus Labs: Reach and Market Position

On the Divi's Laboratories side of the Divi's Laboratories vs Laurus Labs comparison, Divi's Laboratories manufactures custom synthesis APIs and generic APIs for global pharma innovators and generics companies. Its manufacturing is concentrated in two large sites in Visakhapatnam, Andhra Pradesh. Market capitalisation is Rs 2,21,666 Cr.

Click Here – Get Free Investment Predictions

On the Laurus Labs side of the Divi's Laboratories vs Laurus Labs comparison, Laurus Labs manufactures ARV APIs, oncology APIs, CDMO APIs and formulations from multiple Hyderabad-based manufacturing sites. It has diversified from ARV into oncology and CDMO in recent years. Market capitalisation is Rs 99,563 Cr.

Divi's Laboratories vs Laurus Labs: Key Products and Business Mix

In the Divi's Laboratories vs Laurus Labs product comparison, Divi's Laboratories offers: Divi's earns from custom synthesis, generic API and nutraceutical ingredient manufacturing. EPS is Rs 110.18. P/E is 75.79x, ROE 15.32 percent, zero debt. Dividend yield is 0.36 percent.

For Laurus Labs in this Divi's Laboratories vs Laurus Labs breakdown: Laurus Labs earns from ARV API (supply to WHO-procured tenders), oncology API, formulations and CDMO services. EPS is Rs 20.18. P/E is 91.31x, ROE 16.77 percent, D/E 0.48.

Divi's Laboratories vs Laurus Labs: Latest Results

The Divi's Laboratories vs Laurus Labs results for Divi's Laboratories: Divi's has a market cap of Rs 2,21,666 Cr and P/E of 75.79x. ROE is 15.32 percent with zero debt — reflecting its asset-heavy but cash-generative manufacturing model. Divi's is roughly 2.2 times larger than Laurus Labs by market cap.

The Divi's Laboratories vs Laurus Labs results for Laurus Labs: Laurus Labs has a market cap of Rs 99,563 Cr and P/E of 91.31x. ROE is 16.77 percent with moderate D/E of 0.48. Laurus has been investing in capacity for oncology and CDMO, which compresses near-term ROE but positions it for diversification.

Compare Divi's Laboratories and Laurus Labs Fundamentals on the Univest Screener

Divi's Laboratories vs Laurus Labs: Stock and Valuation

The Divi's Laboratories vs Laurus Labs stock comparison uses the latest available market data from Groww. Investors tracking Divi's Laboratories vs Laurus Labs should verify current prices on NSE or BSE before trading.

Divi's Labs vs Laurus Labs at current valuations: Divi's trades at Rs 2,21,666 Cr market cap, P/E 75.79x, ROE 15.32 percent, zero debt. Laurus trades at Rs 99,563 Cr market cap, P/E 91.31x, ROE 16.77 percent, D/E 0.48. Both trade at premium P/E multiples that reflect the steady cash flow and oligopolistic nature of API manufacturing.

Divi's Laboratories vs Laurus Labs: Quick Comparison Table

The Divi's Laboratories vs Laurus Labs comparison table below summarises the key metrics covered in this article side by side.

Parameter	Divi's Laboratories	Laurus Labs
Sector	Custom synthesis + generic API	ARV API + oncology + CDMO + formulations
Market Cap	Rs 2,21,666 Cr	Rs 99,563 Cr
P/E Ratio	75.79x	91.31x
ROE	15.32%	16.77%
Debt to Equity	Zero	0.48
Dividend	0.36% yield	0.11% yield
Key Strength	Custom synthesis dominance, quality	ARV API volumes + oncology growth

Conclusion

The Divi's Laboratories vs Laurus Labs comparison above covers the key data points on reach, products, results and valuation. Divi's Laboratories vs Laurus Labs covers two of India's premium API manufacturers at different scale and diversification points. Divi's is the scale and quality leader with zero debt and a dominant custom synthesis franchise. Laurus is a high-growth API company diversifying from ARV into oncology and CDMO. Both are structurally important to global pharma supply chains. Investors should review API molecule mix, customer concentration, CDMO order book and capex plans before taking a view. Consult a SEBI-registered advisor for personalised guidance.

Download the Univest iOS App or Univest Android App to track Divi's Laboratories and Laurus Labs live price and get daily stock recommendations.

SEBI Research Analyst Registration No. INH000013776

Frequently Asked Questions

What does Divi's Laboratories make?

Ans. Divi's Laboratories makes custom synthesis APIs for global pharma innovators (molecules under patent protection) and generic APIs (off-patent molecules). It is one of the world's preferred CDMO partners for complex chemistry.

What does Laurus Labs make?

Ans. Laurus Labs makes ARV (antiretroviral) APIs for HIV treatment globally, oncology APIs, and is building a CDMO business for custom synthesis. It also makes formulations including FDF for export.

Does Divi's have any debt?

Ans. Divi's Laboratories has zero debt on its balance sheet, funded entirely through internal accruals and equity, which is unusual for a capital-intensive pharma manufacturer.

Is Divi's Laboratories a good investment?

Ans. Divi's is considered a high-quality pharma API franchise with consistent ROE and zero debt. Investors should review new molecule ramp-up, capex announcements and client diversification. Consult a SEBI-registered advisor.

Which is larger, Divi's or Laurus?

Ans. Divi's Laboratories is larger at Rs 2,21,666 Cr versus Laurus Labs at Rs 99,563 Cr.

What is a CDMO?

Ans. CDMO stands for Contract Development and Manufacturing Organisation. CDMOs provide end-to-end services from molecule development through clinical API supply to commercial-scale manufacturing for pharma innovators.

Are they in Nifty 50?

Ans. Divi's Laboratories is in Nifty 50. Laurus Labs is not in Nifty 50.